To provide the information your oncologist is not telling you or doesn't have the time to!
Here, we delve into the dynamic world of cutting-edge cancer treatments and therapies. Stay informed about groundbreaking advancements in cancer care, from emerging therapies to novel treatment modalities. Discover how science and technology are shaping the future of oncology, offering new hope and possibilities to those affected by cancer. Join us as we explore innovative approaches that hold the promise of brighter tomorrows for patients and their families.
On December 13, 2023, the Food and Drug Administration (FDA) achieved a significant breakthrough by granting approval to eflornithine (IWILFIN, USWM, LLC) for use in both adult and pediatric patients facing the challenges of high-risk neuroblastoma (HRNB). This groundbreaking decision marks the first-ever FDA approval of a therapy designed to reduce the risk of relapse …
In a groundbreaking move, the Food and Drug Administration (FDA) has granted approval for enzalutamide (Xtandi, Astellas Pharma US, Inc.) to address non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence. This significant development brings renewed hope for patients at high risk for metastasis. The Road to Approval: EMBARK Trial Insights In the EMBARK clinical trial …
The latest development in breast cancer treatment brings hope and progress. On November 16, 2023, the Food and Drug Administration (FDA) approved capivasertib, in combination with fulvestrant, for adult patients battling hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This approval marks a significant step forward for …
by Sajeve Thomas, MD, Oncologist Biliary tract cancer (BTC), a rare and aggressive form of cancer affecting the bile ducts, gallbladder, and liver, has historically been challenging to treat. However, there is hope on the horizon with the recent FDA approval of pembrolizumab (Keytruda, Merck) in combination with chemotherapy. This groundbreaking development offers new possibilities …
On November 7, 2023, the Food and Drug Administration (FDA) made significant updates to the existing indication of pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. These changes come as part of the FDA’s commitment to advancing cancer treatment options, bringing …
Shifting the Paradigm of Cancer Treatment In previous posts on MedOncMD.com, I’ve discussed a message about a future where we rely less on traditional chemotherapy. Dr. Thomas and I have dedicated a significant portion of our careers to shifting the paradigm toward more targeted therapies that minimize damage to healthy cells. Our ultimate goal is …
Traditional Treatment Approaches for Hodgkin’s Lymphoma Lymphomas encompass a diverse group of blood cancers, with various types and treatment approaches depending on factors such as lymphoma subtype, origin, and aggressiveness. One particular lymphoma subtype with unique treatment options is Hodgkin’s lymphoma. Traditionally, in the United States, Hodgkin’s lymphoma has been treated with a chemotherapy combination …
In terms of cancer diagnoses, the more common ones we hear of are cancers such as Leukemia, Lymphoma, melanoma, and breast cancer. But what about Leiomyosarcoma?
Leiomyosarcoma is a rare and aggressive form of cancer that develops in the smooth muscles of the body (i.e. intestines, stomach, uterus, blood vessels).
One of the most vivid metaphors for chemotherapy is that of a bomb: it obliterates both good and bad cells, with the hope that only the good ones regenerate. While traditional chemotherapy remains a significant tool in cancer treatment, there’s been a recent shift towards more precise therapies that selectively target cancer cells. In the …
Article written by one of our Melanoma/Sarcoma Clinical Trial Coordinators Chloe Caldwell to a target audience of healthcare providers regarding a new ongoing protocol for patients dealing with GIST open globally and at the Orlando Health Cancer Institute. All information posted here is publicly available here. Gastrointestinal Stromal Tumors (GIST) constitute a category of soft …